Keilhoff Gerburg, Stang Felix, Goihl Alexander, Wolf Gerald, Fansa Hisham
Institute of Medical Neurobiology, Otto-von-Guericke University, Magdeburg, Germany.
Cell Mol Neurobiol. 2006 Oct-Nov;26(7-8):1235-52. doi: 10.1007/s10571-006-9029-9. Epub 2006 Jun 16.
Demyelination plays a crucial role in neurodegenerative processes and traumatic disorders. One possibility to achieve remyelination and subsequent restoration of neuronal function is to provide an exogenous source of myelinating cells via transplantation. In this context, mesenchymal stem cells (MSCs) have attracted interest. They are multipotent stem cells that differentiate into cells of the mesodermal lineage like bone, cartilage, fat, and muscle. Although adult, their differentiation potential is remarkable, and they are able to transdifferentiate.
We transformed cultivated rat MSCs into myelinating cells by using a cytokine cocktail. Transdifferentiated MSCs were characterized by an enhanced expression of LNGF-receptor, Krox20, and CD104, and a decreased expression of BMP receptor-1A as compared to untreated MSCs. The myelinating capacity was evaluated in vitro and in vivo. Therefore, PC12 cells, normally unmyelinated, were cocultivated with MSCs, transdifferentiated MSCs, and Schwann cells, or the respective cells were grafted into an autologous muscle conduit bridging a 2-cm gap in the rat sciatic nerve. Myelination of PC12 cells was demonstrated by electron microscopy. In vivo, after 3 and 6 weeks regeneration including myelination was monitored histologically and morphometrically. Autologous nerves and cell-free muscle grafts were used as control.
Schwann cells and transdifferentiated MSCs were able to myelinate PC12 cells after 14 days in vitro. In vivo, autologous nerve grafts demonstrated the best results in all regenerative parameters. An appropriate myelination was noted in the Schwann cell groups and, albeit with restrictions, in the transdifferentiated MSC groups, while regeneration in the MSC groups and in the cell-free groups was impaired.
Our findings demonstrate that it may be possible to differentiate MSCs into therapeutically useful cells for clinical applications in myelin defects.
脱髓鞘在神经退行性过程和创伤性疾病中起关键作用。实现髓鞘再生及随后神经元功能恢复的一种可能性是通过移植提供外源性髓鞘形成细胞。在这种情况下,间充质干细胞(MSCs)引起了人们的兴趣。它们是多能干细胞,可分化为中胚层谱系的细胞,如骨、软骨、脂肪和肌肉。虽然是成体干细胞,但其分化潜能显著,并且能够转分化。
我们使用细胞因子鸡尾酒将培养的大鼠间充质干细胞转化为髓鞘形成细胞。与未处理的间充质干细胞相比,转分化的间充质干细胞表现为LNGF受体、Krox20和CD104表达增强,而BMP受体-1A表达降低。在体外和体内评估髓鞘形成能力。因此,将通常无髓鞘的PC12细胞与间充质干细胞、转分化的间充质干细胞和雪旺细胞共培养,或将相应细胞移植到桥接大鼠坐骨神经2厘米间隙的自体肌肉导管中。通过电子显微镜证明PC12细胞的髓鞘形成。在体内,在3周和6周后通过组织学和形态计量学监测包括髓鞘形成在内的再生情况。自体神经和无细胞肌肉移植物用作对照。
雪旺细胞和转分化的间充质干细胞在体外14天后能够使PC12细胞形成髓鞘。在体内,自体神经移植物在所有再生参数方面显示出最佳结果。在雪旺细胞组中观察到适当的髓鞘形成,并且在转分化的间充质干细胞组中尽管有局限性也观察到了髓鞘形成,而间充质干细胞组和无细胞组中的再生受损。
我们的研究结果表明,有可能将间充质干细胞分化为用于髓鞘缺陷临床应用的治疗有用细胞。